1. Home
  2. BIIB vs ARE Comparison

BIIB vs ARE Comparison

Compare BIIB & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • ARE
  • Stock Information
  • Founded
  • BIIB 1978
  • ARE 1994
  • Country
  • BIIB United States
  • ARE United States
  • Employees
  • BIIB N/A
  • ARE N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • ARE Real Estate Investment Trusts
  • Sector
  • BIIB Health Care
  • ARE Real Estate
  • Exchange
  • BIIB Nasdaq
  • ARE Nasdaq
  • Market Cap
  • BIIB 19.9B
  • ARE 17.5B
  • IPO Year
  • BIIB 1991
  • ARE 1997
  • Fundamental
  • Price
  • BIIB $131.32
  • ARE $92.36
  • Analyst Decision
  • BIIB Buy
  • ARE Hold
  • Analyst Count
  • BIIB 27
  • ARE 9
  • Target Price
  • BIIB $220.50
  • ARE $120.00
  • AVG Volume (30 Days)
  • BIIB 1.7M
  • ARE 1.2M
  • Earning Date
  • BIIB 04-23-2025
  • ARE 04-28-2025
  • Dividend Yield
  • BIIB N/A
  • ARE 5.72%
  • EPS Growth
  • BIIB 40.28
  • ARE 233.15
  • EPS
  • BIIB 11.18
  • ARE 1.80
  • Revenue
  • BIIB $9,675,900,000.00
  • ARE $3,123,453,000.00
  • Revenue This Year
  • BIIB N/A
  • ARE N/A
  • Revenue Next Year
  • BIIB N/A
  • ARE $3.88
  • P/E Ratio
  • BIIB $11.75
  • ARE $51.34
  • Revenue Growth
  • BIIB N/A
  • ARE 8.20
  • 52 Week Low
  • BIIB $128.51
  • ARE $90.07
  • 52 Week High
  • BIIB $238.00
  • ARE $130.14
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 32.77
  • ARE 36.52
  • Support Level
  • BIIB $138.65
  • ARE $90.07
  • Resistance Level
  • BIIB $144.07
  • ARE $97.67
  • Average True Range (ATR)
  • BIIB 3.61
  • ARE 2.30
  • MACD
  • BIIB -1.09
  • ARE -0.71
  • Stochastic Oscillator
  • BIIB 14.92
  • ARE 20.54

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

Share on Social Networks: